Trials / Completed
CompletedNCT03276286
Nativis Voyager for Newly Diagnosed GBM
A Feasibility Study of the Nativis Voyager® System in Patients With Newly Diagnosed Glioblastoma Multiforme (GBM)
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 37 (actual)
- Sponsor
- Nativis, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This feasibility study will assess the effects of the Nativis Voyager therapy in patients newly diagnosed with GBM. The study will enroll and treat up to 32 subjects and will be combined with standard of care radiotherapy and temozolomide.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | Nativis Voyager | Nativis Voyager treatment combined with standard of care radiotherapy and temozolomide |
Timeline
- Start date
- 2017-11-10
- Primary completion
- 2022-05-31
- Completion
- 2022-05-31
- First posted
- 2017-09-08
- Last updated
- 2023-02-02
Locations
7 sites across 1 country: United States
Regulatory
- FDA-regulated device study
Source: ClinicalTrials.gov record NCT03276286. Inclusion in this directory is not an endorsement.